Indivior fails to escape class action lawsuit in Suboxone case
Indivior isn’t getting out of its class action Suboxone lawsuit without a trial, a federal judge ruled on Monday.
Judge Mitchell Goldberg of Pennsylvania denied two motions by Indivior for a summary judgment in a case alleging the company committed a “product hop” scheme to prevent generic competition to its opioid addiction treatment Suboxone.
Suboxone, a combination of buprenorphine and naloxone, was approved in tablet form back in 2002 for the treatment of opioid dependence. Indivior, formerly a division of Reckitt Benckiser, developed the drug along with the United States National Institute on Drug Abuse, and received orphan drug exclusivity until October 2009.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.